0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Her2

Her2

Her2 Molecule Information

Name:Receptor protein-tyrosine kinase erbB-2
Target Synonym:HER2 ?Tyrosine kinase-type cell surface receptor HER2?MLN19?Metastatic lymph node gene 19 protein?ERBB2?Proto-oncogene Neu?p185erbB2?CD_antigen=CD340?Proto-oncogene c-ErbB-2?MLN 19?NEU?Receptor tyrosine-protein kinase erbB-2?NGL
Number of Launched Drugs:20
Number of Drugs in Clinical Trials:127
Lastest Research Phase:Approved

Her2 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
HE2-H5212 Human Human Her2 / ErbB2 Protein, Tag Free
HE2-H5212-structure
HE2-H5212-sds
HE2-H5212-elisa_1
HE2-C52Hb Cynomolgus Cynomolgus Her2 / ErbB2 Protein
HE2-C52Hb-structure
HE2-C52Hb-sds
HE2-C52Hb-elisa_1
EHH-V1 Human ELISA Assay Kit for Anti-HER-2 h-mAb in Human Serum
EHH-V1-elisa_1
EHM-V1 Mouse ELISA Assay Kit for Anti-HER-2 h-mAb in Mouse Serum
EHM-V1-elisa_1
EHC-V1 Monkey ELISA Assay Kit for Anti-HER-2 h-mAb in Monkey Serum
EHC-V1-elisa_1
HE2-H82E2 Human Biotinylated Human Her2 / ErbB2 Protein, His Tag, Avi Tag (Avitag™)
HE2-H82E2-structure
HE2-H82E2-sds
HE2-H82E2-elisa_1
HE2-H525x Human Recombinant Human HER2 /ErbB2 (23-450) Protein, C-Fc Tag
HE2-H525x-structure
HE2-H525x-sds
HE2-H822R Human Biotinylated Human Her2 / ErbB2, ultra sensitivity (primary amine labeling, long spacer)
HE2-H822R-structure
HE2-H822R-sds
HE2-H822R-elisa_1
HE2-H5287 Human Human Her2 / ErbB2 Protein, Strep Tag
HE2-H5287-structure
HE2-H5287-sds
HE2-H5287-elisa_1
ER2-M5220 Mouse Mouse Her2 / ErbB2 Protein
ER2-M5220-structure
ER2-M5220-sds
HE2-H5253 Human Human Her2 / ErbB2 Protein, Fc Tag
HE2-H5253-structure
HE2-H5253-sds
HE2-H5253-elisa_1
HE2-H5225 Human Human Her2 / ErbB2 Protein
HE2-H5225-structure
HE2-H5225-sds
HE2-H5225-elisa_1
HE2-H5225-elisa_2

Her2 Molecule Synonym Name

ERBB2,CD340,HER-2/neu,HER2,MLN19,NEU,NGL,TKR1

Her2 Molecule Background

Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer,communication at the neuromuscular junction andregulation of cell growth and differentiation .

Her2 References

Her2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Trastuzumab biosimilar (Biocad) BCD-022 Approved Biocad Breast cancer Details
Afatinib Dimaleate BIBW-2992; BIBW-2992-MA2,BIBW 2992,BIBW2992 Approved Boehringer Ingelheim GILOTRIF fda Metastatic squamous non-small cell lung cancer (NSCLC), Non small cell lung cancer (NSCLC) BOEHRINGER INGELHEIM 2013-07-12 Metastatic squamous non-small cell lung cancer (NSCLC), Non small cell lung cancer (NSCLC) Details
Trastuzumab biosimilar (Zydus) Approved Zydus cadila Breast cancer Details
Trastuzumab RO45-2317; Anti-HER2/neu-MAb; MKC-454; R-597; RG-597; huMAb4D5-8,RO452317 Approved Genentech, Chugai HERCEPTIN fda Gastric cancer, Breast cancer GENENTECH 1998-09-25 Gastric cancer, Breast cancer, Metastatic gastric carcinoma, Gastroesophageal junction adenocarcinoma Details
Trastuzumab biosimilar (Reliance Life Sciences) R-TPR-016 Approved Reliance Life Sciences Breast cancer Details
Trastuzumab biosimilar (AXXO) Approved AXXO Breast cancer Details
Trastuzumab biosimilar (Celltrion) CT-P06; CT-P6,CTP06; CTP6,CTP06; CTP6; CTP-06 Approved Celltrion, Nippon Kayaku, Teva trastuzumab ema Celltrion Healthcare Hungary Kft. 2018-02-09 Gastric cancer, Breast cancer Details
Trastuzumab biosimilar (Nippon Kayaku) Approved Nippon Kayaku Trastuzumab biosimilar (Nippon Kayaku) 日本 Metastatic gastric carcinoma 日本化药株式会社 2018-03-23 00:00:00.0 Metastatic gastric carcinoma Details
Trastuzumab biosimilar (Allergan/Amgen) ABP-980,ABP980; ABP 980 Approved Synthon, Allergan, Daiichi Sankyo, Amgen trastuzumab ema Amgen Europe B.V., Breda 2018-05-16 Gastric cancer, Breast cancer Details
Neratinib Maleate CAN-030; HKI-272; PB-272; PF-0528767; WAY-179272 Approved Pfizer, Puma Biotechnology, CANbridge Life Sciences NERLYNX fda HER2-positive metastatic breast cancer PUMA BIOTECH 2017-07-17 HER2-positive metastatic breast cancer Details
Lapatinib Ditosylate Hydrate GW-572016F; GW-572016; GW-2016,GW572016,GW 572016F,GW572016F,GW 572016 Approved GlaxoSmithKline, Novartis TYKERB fda Breast cancer NOVARTIS PHARMS CORP 2007-03-13 ER positive metastatic breast cancer, HR-negative/HER2-positive metastatic breast cancer, Breast cancer, HER2-positive metastatic breast cancer, HER2-positive advanced breast cancer Details
Trastuzumab biosimilar (Dr. Reddy's Laboratories) Approved Dr Reddys Laboratories Breast cancer Details
Trastuzumab-dkst Bmab-200; Myl-1401O Approved Biocon, Mylan OGIVRI fda MYLAN GMBH 2017-12-01 Gastric cancer, Breast cancer, Gastroesophageal junction adenocarcinoma Details
Ado-trastuzumab emtansine T-DM1; PRO-132365; R-3502; RG-3502; RO-5304020 Approved Genentech, Chugai KADCYLA fda Breast cancer GENENTECH 2013-02-22 Breast cancer, HER2-positive metastatic breast cancer Details
Trastuzumab biosimilar (Samsung Bioepis) SB3 Approved Samsung Bioepis, Merck Sharp & Dohme trastuzumab ema Samsung Bioepis UK Limited (SBUK) 2017-11-15 Gastric cancer, Breast cancer Details
Trastuzumab biosimilar (AryoGen Pharmed) Approved AryoGen Biopharma Gastric cancer, Breast cancer Details
Dacomitinib PF-00299804; PF-299; PF-299804; PF-804; PF-00299804-03; PF-00299804-3,PF00299804,PF299804,PF299 Approved Pfizer, SFJ pharmaceuticals VIZIMPRO fda Non small cell lung cancer (NSCLC) PFIZER INC 2018-09-27 Non small cell lung cancer (NSCLC) Details
Pertuzumab rhuMab-2C4; R-1273; RG-1273; RO-4368451-F01; RO-4368451 Approved Genentech, Chugai PERJETA fda Breast cancer GENENTECH 2012-06-08 Breast cancer, HER2-positive metastatic breast cancer Details
Pyrotinib Maleate SHR-1258; BLTN; HTI-1001 Approved Jiangsu Hengrui Medicine Pyrotinib Maleate Tablets cfda HER2-positive metastatic breast cancer 2018-08-12 HER2-positive metastatic breast cancer Details
Trastuzumab biosimilar (Pfizer) PF-05280014; PF-5280014,PF05280014; PF5280014 Approved Pfizer trastuzumab ema Pfizer Europe MA EEIG 2018-07-26 Breast cancer Details

Her2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
IDN-6439 IDN-6439 Preclinical Indena Head and neck cancer Details
Trastuzumab glyco-optimised (Glycotope) GT-Mab-7.3-GEX Phase Ⅱ Glycotope Gastric cancer, Breast cancer Details
Anti-HER2 small molecule imaging agent (Affibody) 68GaABY025; ABY-002; ABY-0125; ABY-025 Phase Ⅲ Affibody Breast cancer Details
Trastuzumab biosimilar (Intas Pharmaceuticals) Phase Ⅲ Intas Biopharmaceuticals Breast cancer Details
Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) Phase Ⅰ National Cancer Institute Solid tumours Details
ADCT 502 (ADC Therapeutics) ADCT-502 Phase Ⅰ Cancer Research Technology, ADC Therapeutics Solid tumours Details
Trastuzumab biosimilar (Hualan Biological Engineering) Phase Ⅰ Hualan Biological Engineering Metastatic gastric carcinoma, Metastatic breast cancer Details
Trastuzumab biosimilar (BIOCND/Genor Biopharma) GB-221,GB221 Phase Ⅲ Genor Biopharma Breast cancer Details
AU-101 AU-101 Phase Ⅱ Aurora BioPharma Breast cancer, Osteosarcoma, Glioblastoma Details
RG-6194 RG-6194; BTRC-4017A Phase Ⅰ Roche Solid tumours Details
Pirotinib Hydrochloride KBP-5209,KBP5209 Phase Ⅱ XuanZhu Pharma Non small cell lung cancer (NSCLC), Breast cancer, Lung cancer Details
MEDI-4276 MEDI-4276 Phase Ⅰ MedImmune Gastric cancer, Breast cancer Details
RG-6148 DHES-0815A; RG-6148 Phase Ⅰ Roche HER2-positive breast cancer Details
Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) Phase Ⅰ Qilu Pharmaceutical Breast cancer Details
Mubritinib TAK-165,TAK165 Phase Ⅰ Takeda Breast cancer Details
Trastuzumab biosimilar (CTTQ Pharma) Phase Ⅰ Chiatai Tianqing (CTTQ) Breast cancer Details
CP-724714 CP-724714; CP-724,714 ,CP724714,CP-724,714 Phase Ⅱ Pfizer Metastatic breast cancer Details
Varlitinib Ditosylate ARRY-543; ARRY-00334543; ASLAN-001; ARRY-334543; QBT-01; SPS-4370,ARRY543 Phase Ⅲ Array BioPharma Gastric cancer, Breast cancer, Solid tumours, Hepatocellular carcinoma (HCC), Pancreatic cancer, Biliary cancer Details
LCB14-0110 IND Filing LegoChemBio, Fosun Pharma Gastric cancer, Breast cancer, Solid tumours Details
Anti-HER2 ribozyme (Elan/Sirna) Phase Ⅰ Elan Pharm, Merck Breast cancer, Ovarian cancer Details
Margetuximab MGAH-22,MGAH22 Phase Ⅲ MacroGenics, Green Cross HER2-positive metastatic breast cancer Details
Trastuzumab biosimilar (Hanwha Biologics) HD-201,HD201; HD 201 Phase Ⅲ Hanwha Biologics Gastric cancer, Breast cancer Details
NJH-395 NJH-395,NJH 395,NJH395 Phase Ⅰ Novartis Cancer Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306,AST6,ALS-1306 Phase Ⅱ Shanghai Allist Pharmaceuticals Breast cancer, Lung cancer Details
PX-1031 (Pharmexa) PX-1031; PX-103.1; ME-103.1.1; ME-103 Phase Ⅱ Pharmexa Breast cancer Details
AC-480 AC-480; BMS-599626 ,AC480; BMS599626 ,AC 480; BMS 599626 Phase Ⅰ Ambit biosciences Glioma, Solid tumours Details
Cancer vaccine (Merck & Co/Vical) ,V-930,V-932 Phase Ⅰ Merck Sharp & Dohme, Vical Non small cell lung cancer (NSCLC), Breast cancer, Colorectal cancer, Ovarian cancer Details
MRG002 MRG-002 Phase Ⅰ Shanghai Miracogen Gastric cancer, Breast cancer Details
Irbinitinib; Tucatinib ONT-380; ARRY-380; 234248D0HH,ARRY380,ONT380,Tucatinib Phase Ⅱ Array BioPharma, Cascadian Therapeutics Breast cancer Details
GB-251 GB-251,GB251 Phase Ⅰ Genor Biopharma HER2-positive metastatic breast cancer Details
Ertumaxomab Phase Ⅱ Trion Pharma, NeoPharm Breast cancer Details
HER2.taNK NK-92/5.28.z Phase Ⅰ NantKwest Glioblastoma Details
CUDC-101 CUDC-101,CUDC101 Phase Ⅰ Curis Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Hepatocellular carcinoma (HCC), Head and neck cancer Details
SHR-A1201 SHR-A1201 Phase Ⅰ Jiangsu Hengrui Medicine HER2-positive metastatic breast cancer Details
TAK-285 TAK-285,TAK285 Phase Ⅰ Takeda Solid tumours Details
Trastuzumab biosimilar (Bionovis/The Instituto Vital Brazil) Phase Not Specified Bionovis, The Instituto Vital Brazil Gastric cancer, Breast cancer, Metastatic breast cancer Details
KSP-910638-G KSP-910638-G; KSP-910638G,KSP 910638G; KSP-910638G Phase Ⅰ University of Michigan Gastrointestinal cancer Details
Pelitinib EKB-569; WAY-EKB-569,EKB569,WAY EKB569 Phase Ⅱ Pfizer Non small cell lung cancer (NSCLC), Colorectal neoplasms Details
Iodine-131-SGMIB anti-HER2 monoclonal antibody 131I-SGMIB-anti-HER2-VHH1; [131I]-SGMIB Anti-HER2-VHH1; CAM-H2; Iodine-131-SGMIB-anti-HER2-VHH1 Phase Ⅰ Camel-IDS Breast cancer Details
Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) Phase Ⅰ Shanghai Pharma, Shanghai Jiaolian HER2-positive breast cancer Details
GBR-1302 GBR-1302 Phase Ⅰ Glenmark Pharma, Harbour BioMed Solid tumours Details
Sapitinib AZD-8931,AZD8931 Phase Ⅱ AstraZeneca Non small cell lung cancer (NSCLC), Metastatic breast cancer Details
ALT-P7 HM2-MMAE; ALT-P7 Phase Ⅰ Alteogen, 3SBio Gastric cancer, Breast cancer Details
AE-37/GP-2 vaccine AE-37 Phase Ⅱ Generex Biotechnology Corporation Prostate cancer, Breast cancer Details
KN-026 KN-026,KN026 Phase Ⅰ Alphamab Gastric cancer, Breast cancer Details
BMS-690514 BMS-690514,BMS690514 Phase Ⅱ Bristol-Myers Squibb Non small cell lung cancer (NSCLC), Breast cancer Details
A-166 A-166,A166 Phase Ⅰ Kelun Pharmaceutical Gastric cancer, HER2-positive breast cancer Details
ADXS-31164 ADXS31-164; ADXS-31164; ADXS-cHER2; ADXS-HER2 Phase Ⅰ University of Pennsylvania, Advaxis Solid tumours, Osteosarcoma Details
GB-235 GB-235,GB235 Phase Ⅰ Genor Biopharma HER2-positive breast cancer Details
Trastuzumab biosimilar (STC Biologics) STC-101 Phase Ⅰ STC Biologics Solid tumours Details
MP-412 AV-412; MP-412,MP412,AV412 Phase Ⅱ Mitsubishi Tanabe Pharma Solid tumours Details
Hemay-022 Hemay-022,Hemay022 Phase Ⅰ Tianjin Hemay Biotech, Xia Jiang Hemay Pharmaceutical HER2-positive breast cancer Details
Recombinant anti-HER2 antibody (Anke Biotech) Phase Ⅲ Anke Biotechnology Breast cancer Details
Selatinib Ditosilate QLNC-120,QLNC120 Phase Ⅰ Qilu Pharmaceutical, Qilu Antibiotics (Linyi) Pharmaceutical Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer Details
ICT-140 ICT-140 Preclinical ImmunoCellular Therapeutics Ovarian cancer Details
AEE-788 AEE-788; NVP-AEE-788,AEE788,NVPAEE788 Phase Ⅱ Novartis Glioblastoma multiforme Details
TAA013 TAA-013,TAA013; TAA 013 Phase Ⅰ TOT Biopharm Solid tumours Details
Anti-CD3-anti-HER2-activated T cells Phase Ⅱ TransTarget, Barbara Ann Karmanos Cancer Institute, National Cancer Institute Breast cancer Details
Trastuzumab biosimilar (Tanvex Biopharma) TX-05 Phase Ⅲ Tanvex BioPharma Breast cancer Details
Anti-HER2 antibody toxin conjugate (TopoTarget) Phase Ⅰ Novartis, Topotarget Cancer Details
Trastuzumab duocarmazine SYD-985,SYD985; SYD 985 Phase Ⅲ Synthon Gastric cancer, Breast cancer, Solid tumours Details
ETBX-021 ETBX-021 Phase Ⅰ Etubics Corporation, NantBioScience Breast cancer Details
Recombinant human ErbB3 fragment vaccine (Zensun) rhErbB3-f Phase Ⅰ Zensun Solid tumours Details
Tesevatinib EXEL-7647; KD-019; KD-020; XL-647,KD019,EXEL7647,KD020,XL647 Phase Ⅲ Exelixis, Kadmon Non small cell lung cancer (NSCLC), Autosomal dominant polycystic kidney disease (ADPKD) Details
Trastuzumab biosimilar (United BioPharma) UB-921 Phase Ⅰ United BioPharma Breast cancer Details
Recombinant anti-HER2 humanized monoclonal antibody-DM1 (Qilu Pharmaceutical) Phase Ⅰ Qilu Pharmaceutical Breast cancer Details
TPIV-100 (TapImmune) TPIV-100 Phase Ⅰ Mayo Clinic, TapImmune Breast cancer Details
IBPM002BZ (Inbiopro Solutions) IBPM-002BZ Phase Not Specified Inbiopro Solutions Small cell lung cancer (SCLC), Renal cell carcinoma, Colorectal cancer Details
XMT-1522 TAK-522; XMT-1522 Phase Ⅰ Mersana Therapeutics, Adimab, Takeda Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer Details
anti-HER2 ADC (Pfizer) PF-06804103 Phase Ⅰ Pfizer Solid tumours Details
Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) Phase Ⅰ Seattle Children's Research Institute Central nervous system tumors Details
HER2 cancer vaccine (BioLife Science) IMU-131; PEV-6A; PEV-6,IMU 131; PEV 6A; PEV 6,IMU131; PEV6A; PEV6 Phase Ⅱ Pevion Biotech, Imugene, Mymetics Corporation Gastric cancer, Esophagus cancer, Breast cancer Details
BAT-8001 BAT-8001 Phase Ⅲ Bio-Thera Solutions Solid tumours Details
ARX-788 ARX-788 Phase Ⅰ Ambrx, Zhejiang Medicine Solid tumours Details
PB-357 PB-357 Phase Ⅰ Pfizer Solid tumours Details
Trastuzumab deruxtecan DS8201; DS8201a,DS-8201; DS-8201a; fam-trastuzumab deruxtecan Phase Ⅲ Daiichi Sankyo, Bristol-Myers Squibb, Puma Biotechnology Urogenital cancer, Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Colorectal cancer, Cervical carcinoma Details
Recombinant anti-HER2 subdomain II humanized monoclonal antibody (Livzon Group) LZM-005 Phase Ⅰ Livzon Group Livzon Pharmaceutical Factory HER2-positive metastatic breast cancer, HER2-positive breast cancer Details
IBPM003TZ (Inbiopro Solutions) IBPM-003TZ Phase Not Specified Inbiopro Solutions Breast cancer Details
tgDCC-E1A gene therapy (Targeted Genetics) Phase Ⅱ Targeted Genetics Breast cancer, Ovarian cancer, Head and neck cancer Details
MVA-BN-HER2 PX-1032 Phase Ⅱ Pharmexa, Bavarian Nordic Breast cancer Details
AU-105 AU-105 Phase Ⅱ Aurora BioPharma Glioblastoma multiforme Details
Trastuzumab biosimilar (EirGenix) EG-12014 Phase Ⅰ EirGenix Breast cancer Details
SHR-1309 SHR-1309,SHR1309 Phase Ⅰ Jiangsu Hengrui Medicine HER2-positive metastatic breast cancer Details
PKI-166 CGP-75166; PKI-166; PKI-75166 Phase Ⅱ Novartis Solid tumours Details
Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) Phase Ⅰ Shenzhen Main Luck Pharmaceuticals Breast cancer Details
BVAC-B vaccine (Cellid) BVAC-B Phase Ⅰ Cellid Company Gastric cancer Details
M-802 M-802,M802; M 802 Phase Ⅰ YZY Bio Gastric cancer, HER2-positive breast cancer Details
Recombinant anti-HER2 humanized monoclonal antibody complex Phase Ⅰ Shanghai Pharma HER2-positive breast cancer Details
Sym-013 Sym-013,Sym 013,Sym013 Phase Ⅱ Symphogen Cancer Details
Recombinant humanized anti-EGFR monoclonal antibody (Hisun Pharm/Mabworks Biotech) HS627 Phase Ⅰ Beijing Mabworks Biotech, Hisun Pharm Breast cancer Details
Trastuzumab biosimilar (Shanghai CP Guojian) CMAB-302 BLA Filing Shanghai CP Guojian Breast cancer Details
212 Pb-trastuzumab Phase Ⅰ Areva Pharmaceuticals, University of Alabama at Birmingham, University of Cincinnati Metastatic cancer Details
Trastuzumab biosimilar (Gedeon Richter) Preclinical Gedeon Richter, STADA Arzneimittel Gastric cancer, Breast cancer Details
Trastuzumab biosimilar (BioXpress Therapeutics) BX-2318 Phase Not Specified BioXpress Therapeutics SA Breast cancer Details
Trastuzumab biosimilar (Alteogen/Cristalia/Qilu Pharmaceutical) ALT-02,ALT-L2 Phase Ⅰ Alteogen, Cristalia, Qilu Pharmaceutical Gastric cancer, Breast cancer Details
Gancotamab (Merrimack) MM-302 Phase Ⅲ Merrimack, Baxter, Johnson & Johnson Breast cancer Details
MDX H210 Phase Ⅱ Medarex Prostate cancer, Breast cancer Details
HER2-antigen specific cancer vaccine HER2-ASCI Phase Ⅱ GlaxoSmithKline Breast cancer Details
MM-111 MM-111 Phase Ⅱ Merrimack Gastric cancer, Esophagus cancer, Breast cancer, Solid tumours Details
Canertinib Dihydrochloride CI-1033; PD-0183805; PD-183805 ,CI1033, PD 0183805,PD 183805 Phase Ⅱ Pfizer Non small cell lung cancer (NSCLC), Breast cancer, Ovarian cancer, Head and neck cancer Details
Cipatinib Tosylate Phase Ⅰ Hansoh Pharma, Shanghai Pharma Breast cancer, Lung cancer Details
BMS-986186 BMS-986186; FS-102 Phase Ⅰ F-star, Bristol-Myers Squibb Gastric cancer, Breast cancer, Solid tumours Details
AP-32788 TAK-788; AP-32788 Phase Ⅱ Ariad Non small cell lung cancer (NSCLC) Details
MCLA-128 MCLA-128,MCLA128; MCLA 128 Phase Ⅱ Merus Non small cell lung cancer (NSCLC), Gastric cancer, Endometrial cancer, Solid tumours, Metastatic breast cancer, Ovarian cancer Details
Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) Phase Ⅰ Beijing Mabworks Biotech, Hisun Pharm Breast cancer Details
Pertuzumab biosimilar (CTTQ) Phase Ⅰ Chiatai Tianqing (CTTQ) HER2-positive metastatic breast cancer Details
Autologous-HER2-specific-T-cells Autologous-HER2-specific-T-cells Phase Ⅰ Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System Sarcoma Details
TGFBeta-resistant-HER2-EBV-CTLs TGFBeta-resistant-HER2-EBV-CTLs Phase Ⅰ Baylor College of Medicine, Methodist Hospital System Malignancies Details
Tarloxotinib Bromide TH-4000; PR-610; SN-33999,TH4000,PR610,SN-33999 Phase Ⅱ Threshold Non small cell lung cancer (NSCLC), Squamous cell carcinoma of head and neck cancer (SCCHN) Details
Bispecific monoclonal antibody 2B1 Phase Ⅰ Chiron Cancer Details
Epertinib S-222611,S222611 Phase Ⅱ Shionogi Solid tumours Details
MBS301 MBS-301 ,MBS301; MBS 301 Phase Ⅰ Beijing Mabworks Biotech Gastric cancer, HER2-positive breast cancer Details
Breast cancer vaccine HER-2/neu (GlaxoSmithKline) Phase Ⅱ GlaxoSmithKline Breast cancer Details
HS-10182 HS-10182,HS10182 Phase Ⅰ Hansoh Pharma Solid tumours Details
MX-402 MX-402,MX 402,MX402 Phase Ⅰ MedVax Technologies Gastric cancer Details
Lapuleucel-T APC-8024; BA-7072; DN-2402 Phase Ⅱ Dendreon Corporation Urogenital cancer Details
ZW-25 ZW-25 Phase Ⅰ Zymeworks Gastric cancer, Breast cancer, Ovarian cancer Details
Trastuzumab biosimilar (Dong-A ST/Meiji Seika Pharma) DA-3111; DMB-3111 Phase Ⅰ Dong-A Pharmaceutical, Meiji Seika Pharma Gastric cancer, Breast cancer Details
Poziotinib HM-78136; HM-78136B; NOV1201; NOV-120101,Poziotinib,HM78136B,NOV120101,HM-78136,NOV1201,HM781-36B Phase Ⅱ Hanmi, Luye Pharma, Spectrum Pharmaceuticals Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Head and neck cancer Details
Trastuzumab conjugate (BioIntegrator) BI-CON-02 Phase Ⅰ BioIntegrator Breast cancer Details
HER.CAR-CMV-specific-CTLs HER.CAR-CMV-specific-CTLs Phase Ⅰ Baylor College of Medicine, Methodist Hospital System, Texas Children's Hospital Glioblastoma multiforme Details
Trastuzumab biosimilar (Shanghai Henlius Biotech) HLX-02 Phase Ⅲ Shanghai Henlius Biotech Breast cancer Details
Trastuzumab-MMAE ADC (Yantai Rongchang Biotechnologies) RC48-ADC; RC-48,RC 48-ADC; RC-48-ADC Phase Ⅱ Yantai Rongchang Biological Engineering HER2-positive metastatic breast cancer Details
Recombinant humanized anti-HER2 antibody (Hisun Pharma) Phase Ⅰ Hisun Pharm HER2-positive metastatic breast cancer Details
MDX-210 MDX-210 Phase Ⅱ Takeda Prostate cancer, Breast cancer, Colorectal cancer, Renal carcinoma Details
CP-347589 CP-347589 Phase Not Specified Pfizer Cancer Details
HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) Phase Ⅱ University of Pennsylvania, National Cancer Institute Breast cancer Details

This web search service is supported by Google Inc.

totop